Cell Therapeutics to pay $10.5 million for off-label promotion

04/17/2007 | SeattlePI.com

Cell Therapeutics, a Seattle biotech, agreed to pay the U.S. government $10.5 million over allegations that the firm promoted its Trisenox cancer drug for off-label uses, resulting in the submission of false claims for reimbursement to Medicare. The firm, which sold Trisenox to another firm in July 2005, did not admit wrongdoing in the agreement.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI